DeepMed Research

University of Minnesota Masonic Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Allo HSCT for High Risk Hemoglobinopathies

Phase 2

Recruiting

Conditions: Graft Failure
Sickle Cell Disease
Hemoglobinopathies

Interventions: Drug: Alemtuzumab
Radiation: Total Body Irradiation
Drug: Thymoglobulin
Biological: Cell Infusion
Drug: Fludarabine
Drug: Sirolimus
Drug: Busulfan
Drug: Tacrolimus
Drug: Thiotepa
Drug: Cyclophosphamide
Drug: Mycophenolate Mofetil

First Posted Date: 2025-03-12

Last Posted Date: 2025-03-12

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 62

Registration Number: NCT06872333

Locations: 🇺🇸
Masonic Cancer Center, Minneapolis, Minnesota, United States

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

Phase 2

Not yet recruiting

Conditions: Follicular Lymphoma
Marginal Zone Lymphoma

Interventions: Drug: Tafasitamab
Drug: Rituximab
Drug: Lenalidomide

First Posted Date: 2025-01-27

Last Posted Date: 2025-01-27

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 65

Registration Number: NCT06792825

Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies

Not Applicable

Not yet recruiting

Conditions: Solid Tumor, Adult
Cytotoxicity

Interventions: Other: Placebo
Biological: Lactobacillus and Bifidobacterium

First Posted Date: 2025-01-13

Last Posted Date: 2025-03-06

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 40

Registration Number: NCT06772090

Adenovirus (RGDCRAdCOX2F)

Phase 1

Recruiting

Conditions: Adenocarcinoma of Pancreas

Interventions: Biological: Replicative Adenovirus Vector (RGDCRAdCOX2F)

First Posted Date: 2024-11-19

Last Posted Date: 2024-12-30

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 18

Registration Number: NCT06693986

Locations: 🇺🇸
Masonic Cancer Center, Minneapolis, Minnesota, United States

Trial of Cell Based Therapy for DMD

Phase 1

Recruiting

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: MyoPAXon
Drug: Tacrolimus

First Posted Date: 2024-11-18

Last Posted Date: 2025-03-24

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 8

Registration Number: NCT06692426

Locations: 🇺🇸
Masonic Cancer Center, Minneapolis, Minnesota, United States

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

Phase 1

Recruiting

Conditions: Myeloid Malignancy
Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: GTB-360

First Posted Date: 2024-09-19

Last Posted Date: 2025-02-10

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 45

Registration Number: NCT06594445

Locations: 🇺🇸
Masonic Cancer Center, Minneapolis, Minnesota, United States

Rural Smoking Cessation

Not Applicable

Not yet recruiting

Conditions: Smoking Cessation

Interventions: Drug: Nicoderm CQ nicotine patch
Drug: Nicorette Nicotine Lozenges

First Posted Date: 2024-09-05

Last Posted Date: 2025-01-16

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 272

Registration Number: NCT06584929

American Indian Smokefree Native RCT

Not Applicable

Recruiting

Conditions: Smoking Cessation

Interventions: Other: Smoking Cessation Program
Other: Cultural Smoking Cessation Program

First Posted Date: 2024-08-09

Last Posted Date: 2025-04-20

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 416

Registration Number: NCT06544811

Locations: 🇺🇸
Masonic Cancer Center, Minneapolis, Minnesota, United States

Remote Trial - Tobacco Product Standard (VLNC)

Not Applicable

Terminated

Conditions: Tobacco Use

Interventions: Other: Tobacco and non-tobacco e-cigarettes
Other: Tobacco only e-cigarettes

First Posted Date: 2024-06-04

Last Posted Date: 2025-04-10

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 11

Registration Number: NCT06442384

Locations: 🇺🇸
Masonic Cancer Center, Minneapolis, Minnesota, United States

Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy

Suspended

Conditions: Hematopoietic and Lymphatic System Neoplasm
Malignant Solid Neoplasm

Interventions: Other: Non-Interventional Study

First Posted Date: 2024-05-16

Last Posted Date: 2025-05-20

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 38

Registration Number: NCT06414278

Locations: 🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy